- Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
- Good sales growth in France at +4.6%
- Strong growth in international business thanks to subsidiaries, with sales up +12.6% at constant exchange rates
Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its consolidated sales for the first half of the 2024-25 financial year.
Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "In the first half of the 2024-25 financial year, Amplitude Surgical continued its good momentum following the previous financial year, posting growth of +6.3% at constant exchange rates compared with the first half of 2023-24. This good performance was achieved thanks to growth in the activity of international subsidiaries (+12.6% at constant exchange rates) and the continuation of the good level recorded in France of +4.6%."
Consolidated sales for 1st half 2024-25
Sales H1 2024-25 | 31/12/2024 | 31/12/2023 | Change at current exchange rates | Change at constant exchange rates |
In K€ IFRS | ||||
Knee and hip activities | 51,503 | 49,056 | 5.0% | 6.3% |
Total | 51,503 | 49,056 | 5.0% | 6.3% |
Sales Q2 2024-25 | 31/12/2024 | 31/12/2023 | Change at current exchange rates | Change at constant exchange rates |
In K€ IFRS | ||||
Knee and hip activities | 29,750 | 28,550 | 4.2% | 5.3% |
Total | 29,750 | 28,550 | 4.2% | 5.3% |
In the first half (July-December 2024) of the 2024-25 financial year, Amplitude Surgical sales came to €51.5 million, up +5.0% and +6.3% at constant exchange rates.
Knee and hip business grew in France by +4.6% and internationally by +10.4% at constant exchange rates. Within the international scope, international distributors were up +3.8%, and the Group's international subsidiaries recorded a +6.7% increase at current exchange rates, and a +12.6% increase at constant exchange rates.
Amplitude Surgical's direct sales (French market and international subsidiaries), which account for almost 93% of total Group sales, rose by +6.4% at constant exchange rates.
In France, the Group continued to grow as in the previous year. France accounted for around 71% of Group sales in the first half of the 2024-25 financial year.
International subsidiaries reported growth at constant exchange rates in Belgium, Australia, Brazil and South Africa, while sales in Germany and Switzerland were down.
Next press release:
Half-year results 2024-25: Wednesday, March 26, 2025, after market close.
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery, covering the main pathologies affecting the hip and knee. Working in close collaboration with surgeons, Amplitude Surgical develops numerous high value-added innovations to best meet the needs of patients, surgeons and care facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of agents and exclusive distributors in over 30 countries. As of June 30, 2024, Amplitude Surgical employed 428 people and generated sales of nearly 106.0 million euros.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220756589/en/
Contacts:
Amplitude Surgical
Dimitri Borchtch
Chief Financial Officer
finances@amplitude-surgical.com
04 75 41 87 41
NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
01 44 71 94 94
NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
01 44 71 94 98
